<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184350</url>
  </required_header>
  <id_info>
    <org_study_id>APROVE</org_study_id>
    <nct_id>NCT03184350</nct_id>
  </id_info>
  <brief_title>Adjuvant Protontherapy of Cervical and Endometrial Carcinomas</brief_title>
  <acronym>APROVE</acronym>
  <official_title>Adjuvant Protontherapy of Cervical and Endometrial Carcinomas - A Phase-II-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The APROVE study is a prospective single-center single-arm phase-II study. Patients with
      cervical or endometrial cancer after surgical resection who have an indication for
      postoperative pelvic radiotherapy will be treated with proton therapy instead of the commonly
      used photon radiation. A total of 25 patients will be included in this trial. Patients will
      receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active
      raster-scanning pencil beam proton radiation. Platinum-based chemotherapy can be administered
      if indicated. The primary endpoint of the study is the evaluation of safety and treatment
      tolerability of pelvic radiation using protons defined as the lack of any CTC AE Grade 3 or 4
      toxicity. Secondary endpoints are clinical symptoms and toxicity, quality of life and
      progression-free survival. The aim is to explore the potential of proton therapy as a new
      method for adjuvant pelvic radiotherapy to decrease the dose to the bowel, rectum and bladder
      thus reducing acute and chronic toxicity and improving quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation. Platinum-based chemotherapy can be administered if indicated. For treatment planning rectum, sigma, large and small bowel, bladder and femoral heads are defined as organs at risk. The CTV is defined according to the EORTC consensus guidelines. Treatment-associated toxicity and Quality of life will be evaluated regularly.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute treatment-associated adverse events ≥ grade 3 [Safety and Tolerability]</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of toxicity according to the CTC AE v4.0 (Common Toxicity Criteria for adverse events)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical symptoms according to the CTC AE v4.0. criteria</measure>
    <time_frame>2 years</time_frame>
    <description>clinical symptoms of any grade will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of all patients included in the study</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by the EORTC questionnaires QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of cervical cancer patients included in the study</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by the EORTC questionnaires QLQ-CX24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of endometrial cancer patients included in the study</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by the EORTC questionnaires QLQ-EN24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>regular MRI-scans</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Endometrial Neoplasms Malignant</condition>
  <arm_group>
    <arm_group_label>Adjuvant pelvic proton radiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adjuvant pelvic proton radiation</intervention_name>
    <description>Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation</description>
    <arm_group_label>Adjuvant pelvic proton radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed cervical or endometrial cancer

          -  Indication for postoperative radiotherapy

          -  Karnofsky Index ≥ 70

          -  Age between 18 and 80 years

          -  Written informed consent

        Exclusion Criteria:

          -  patient refusal or patient incapable of consent

          -  implanted active medical devices with no approval for ion beam radiation

          -  metallic implantations in the radiation field like hip prothesis

          -  prior pelvic irradiation

          -  participation in another clinical trial which might influence the results of the
             APROVE trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Debus, Prof.Dr.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Arians, MD</last_name>
    <phone>+496221568202</phone>
    <email>nathalie.arians@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Lossner</last_name>
    <phone>+4962215637748</phone>
    <email>karen.lossner@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of radiation oncology, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Arians, MD</last_name>
      <phone>+496221568202</phone>
      <email>nathalie.arians@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Karen Lossner</last_name>
      <phone>+4962215637748</phone>
      <email>karen.lossner@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Nils Nicolay, PD Dr. Dr.</investigator_full_name>
    <investigator_title>senior physician</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>proton therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

